🔗 Share this article Social Media Influencers Driving Unofficial Trade for Unapproved Weight-Loss Medication An underground economy for unapproved slimming drugs is propelled by social media fitness personalities and vendors on communication apps, according to recent findings. Experimental Treatment Acquiring Popularity Via Social Media Retatrutide, which remains in research studies, is being promoted by online personalities for its supposed fat-burning properties. Viewers are encouraged to message these profiles directly for source information, while also obtaining discount codes. Thriving Trade on Social Networks Additionally, a flourishing trade exists on messaging services, where communities with thousands of members share comparison images, administration instructions and claims of next-day British shipping. Vendors promote the drug there before directing customers to other platforms for transactions. Learning About The Experimental Drug This medication is an investigational injectable developed by US drugmaker Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, GIP and glucagon. Preliminary studies suggest it could help patients lose up to a quarter of their body weight. Referred to as the “triple G”, the substance is being hailed online as the next Ozempic. Healthcare Experts Express Concerns Nevertheless, physicians and pharmacists have cautions that the distribution of what remains an unlicensed drug in the UK is a cause for concern and could lead to users injecting substances of uncertain source. Several experts said the popularity for the experimental drug could be linked to the rising cost of approved slimming treatments such as Mounjaro. Regulatory Position and Enforcement Selling the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unlicensed drug that must not be promoted or distributed for human use under the British medical regulations. Several content creators try to sidestep the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled substance, but advertising and distribution can still breach medicines, advertising, and customer laws, potentially leading to penalties, prosecution or imprisonment. Platform Response and Content Removal Based on the social media company, the service has removed problematic content and banned associated keywords and search suggestions. The company said it was committed to keeping the service secure and allocating resources in strengthening enforcement strategies. Digital Trading Activities Investigations also found communities with up to 9,000 members marketing retatrutide using Telegram's integrated search feature, which operates like a public directory. Typing “retatrutide” instantly displays channels with thousands of users, filled with images of slimming results, positive reviews and step-by-step guides for preparing or injecting at home. Within minutes of entering one group, a seller shared WhatsApp details, where most transactions occur. The seller sent an guidebook and guaranteed delivery within two days. When questioned whether the product was authentic, one vendor responded: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. Not one asked about weight, health issues or past usage. Product Information and Costs Within these groups, posts display dark colored parcels with Royal Mail labels, stating to include new batches. One communication read: “It took eight of us to load them this morning.” Customers can choose between powder vials, prepared at residence with sterile water, or pre-filled pens typically sold at £160 for 20mg. When asked how long a injector should be used, sellers give contradictory responses ranging from a several days to “depends on your body”. Platform Oversight and Safety Actions A representative for the messaging service stated it regularly monitored dangerous material on its service including content that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”. Healthcare Professional Cautions “Individuals are injecting materials they can’t verify. Although the research behind this drug is sound, these online versions may not include what they advertise,” said Jason Murphy, the director of pharmacy at a pharmacy service. Dr Crystal Wyllie of Asda Online Doctor connected the increase in demand to recent cost increases for approved slimming drugs such as Mounjaro. “With prices increasing, individuals are using social media. But fake treatments are extremely risky. You cannot know what’s inside or whether the conditions they were made in was clean,” she explained. Her staff has already encountered patients injured by personal administration from unconfirmed suppliers. “We understand the disappointment, but purchasing from Telegram or communication platforms is gambling with your well-being,” stated Wyllie. “These substances could be contaminated or improperly measured.” Manufacturer Position A representative from the pharmaceutical company said retatrutide was in phase 3 research studies and had not been evaluated or approved by any government authority anywhere in the world. “Consequently at this time no one can sell [it] for personal consumption,” they said, noting that any product “falsely representing itself as a company experimental product not yet approved … may expose patients to potentially significant health risks”.